Resource Type

Journal Article 416

Year

2024 3

2023 25

2022 29

2021 43

2020 27

2019 42

2018 28

2017 31

2016 21

2015 19

2014 16

2013 20

2012 18

2011 11

2010 9

2009 24

2008 12

2007 19

2006 2

2004 4

open ︾

Keywords

immunotherapy 5

hepatocellular carcinoma 4

Cancer 3

cancer immunotherapy 3

invasion 3

mesenchymal stem cells 3

ACE2 2

Biomarkers 2

CAR T cells 2

COVID-19 2

SARS-CoV-2 2

Stem cells 2

Treg 2

cancer 2

carbon-based fuels 2

characterization 2

chimeric antigen receptor T cell 2

cogeneration 2

degradation 2

open ︾

Search scope:

排序： Display mode:

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TThen, activated T cells were infected with retrovirus harvested from stable virus-producing single cloneCAR expression on the surfaces of the T cells was detected by flow cytometry and Western blot.After infection with retrovirus, CAR was expressed on more than 90% of the T cells.The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro.

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.with relapsed or refractory B-cell lymphoma achieved complete remission after receiving the CD19 CAR-Twere greatly expressed on lymphoma cells, were studied under preclinical and clinical evaluations forNonetheless, the CAR-T therapy was usually associated with potentially lethal adverse effects, such asTherefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy with

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallypatient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cellCAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimericantigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50A multi-center phase I/II trial of anti-CD19 CD28z CAR-T (FKC876, ChiCTR1800019661) was conducted.cells, leading to CAR-T cell therapy failure and disease progression in DLBCL.and disease progression, which could not be altered by infiltrating CAR-T cells.Aberrant metabolism profile of M2-subtype macrophages and those of dysfunctional T cells also contributed

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentHowever, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyThe simultaneous expression of target antigens by healthy organs and tumor cells is partly responsibleglycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-TTn, T, and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation    

HTML PDF Collect

involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsed or refractory non-Hodgkin lymphoma (r/r NHL) have not been wellsurvival (OS), and progression-free survival (PFS) in patients with r/r NHL treated with anti-CD19 CAR-Tcells.Thus, anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of Tcells transduced with CBM.CD19 CAR, a second-generation anti-CD19 CAR bearing 4-1BB costimulatory moleculeTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: promote anti-tumor immunity have recently been developed, such as small molecules, bispecific antibodies, chimericantigen receptor T cell products, and cancer vaccines.include agonists and inhibitors that can reach the intracellular or extracellular targets of immune cellsBispecific antibodies, which bind two different antigens or one antigen with two different epitopes,Chimeric antigen receptor T cell products and cancer vaccines have also been investigated.

Keywords： cancer immunotherapy     bispecific antibodies     small molecules     chimeric antigen receptor T therapy     cancer    

HTML PDF Collect

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues Review

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Engineering 2019, Volume 5, Issue 1,   Pages 122-131 doi: 10.1016/j.eng.2018.12.003

Abstract:

Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancerCAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigenson the surface of tumor cells, and then effectively kill tumor cells.At present, exciting results are being achieved in clinical applications of CAR-T cells for patientsThe research and development of CAR-T cells for various targets and for the treatment of solid tumors

Keywords： Chimeric antigen receptor T cells     Quality control     Nonclinical research     Safety     Efficacy     Clinical    

HTML PDF Collect

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Review

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Engineering 2022, Volume 10, Issue 3,   Pages 30-43 doi: 10.1016/j.eng.2021.10.018

Abstract:

Chimeric antigen receptors (CARs) are a breakthrough in genetic engineering that have revolutionizedCells expressing these receptors are rerouted to a predefined target by the inclusion of an antigen-specificThe advantage of cells with programmed specificity has been demonstrated clinically in the field of oncology, and it is clear that such cells have greater accuracy, potency, and reduced off-target therapeuticIn contrast to conventional T cells (Tconvs), regulatory T cells (Tregs) play a major role in suppressing

Keywords： Chimeric antigen receptors     T cell     Treg     Alloimmunity     Bioengineering     Transplant     Autoimmunity    

HTML PDF Collect

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 3-11 doi: 10.1007/s11684-019-0684-x

Abstract: therapy (ACT), such as strategies based on tumor-infiltrating lymphocytes and cytokine-induced killer cellsCurrently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughsThe clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited.Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe sideIn this review, we summarized the current application of ACT, the challenges encountered by CAR-T technology

Keywords： adoptive cell transfer therapy     hepatocellular carcinoma     T cell     chimeric antigen receptor     immunotherapy    

HTML PDF Collect

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 160-184 doi: 10.1007/s11684-020-0750-4

Abstract: immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells

Keywords： immunotherapy     oncolytic virus     genetic modification     immune checkpoint blockade     chimeric antigen receptorT cell    

HTML PDF Collect

Engineered T Cell Therapies from a Drug Development Viewpoint Review

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Engineering 2019, Volume 5, Issue 1,   Pages 140-149 doi: 10.1016/j.eng.2018.11.010

Abstract: Unlike chemical compounds and proteins, cells are living, self-replicating drugs that can be engineeredFor example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowingback against persisting malignant cells.Anti-CD19 chimeric antigen receptor T cells (CART19) have demonstrated a remarkable degree of clinicalWe believe that the success of CART19 will lead to the development of other engineered T cell therapies

Keywords： Engineered T cell therapies     Chimeric antigen receptor     Drug development process     Biomarkers     CAR19    

HTML PDF Collect

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 69-82 doi: 10.1007/s11684-018-0677-1

Abstract:

Cytokine-activated T cells (CATs) can be easily expanded and are widely applied to cancer immunotherapygood efficacy of CATs is rarely reported in clinical applications because CATs have no or very low antigenThe low-efficacy problem can be resolved using T cell antigen receptor-engineered CAT (TCR-CAT).165 HLA-A*02:01-specific high-affinity TCR (HAT)-transduced CATs can specifically kill cancer cellscells (TCR-Ts) in terms of interferon-g and granzyme B production

Keywords： cytokine-activated T cells     high-affinity T cell receptor     cancer immunotherapy     TCR-CAT    

HTML PDF Collect

Title Author Date Type Operation

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimericantigen receptor T therapy

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Journal Article

Emerging immunological strategies: recent advances and future directions

Journal Article

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Journal Article

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Journal Article

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Journal Article

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Journal Article

Engineered T Cell Therapies from a Drug Development Viewpoint

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Journal Article

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Journal Article